Fig. 5

Cyst(e)inase in combination with Olaparib or Auranofin synergistically inhibits growth of PCa xenograft without toxicity. Growth of xenografted 22Rv1 prostate tumors in male nude mice. A Data represents Mean ± SEM of both flank tumors in group of mice treated with vehicle control (n = 14), Cyst(e)inase (n = 15), Olaparib (n = 14), or Cyst(e)inase + Olaparib (n = 14). Two-Way repeated measure ANOVA followed by Bonferroni’s multiple comparison test. ****P < 0.0001, compared to control; # and $, P < 0.01, compared to Cyst(e)inase or Olaparib alone, respectively; B Data represents Mean ± SEM of both flank tumors of group of mice treated with vehicle control (n = 14), Cyst(e)inase 25 mg/kg (n = 15), Auranofin 1 mg/kg (n = 14), Cyst(e)inase 25 mg/kg + Auranofin 1 mg/kg (n = 14) Two-Way repeated measure ANOVA followed by Bonferroni’s multiple comparison test. **P < 0.01, ****P < 0.0001 compared to control; # and $, P < 0.05, compared to Cyst(e)inase or Olaparib alone, respectively; C, D Average body weight per mouse from xenograft tumor studies, (A) and (B), respectively; E Synergistic reduction of tumor growth with combination of Cyst(e)inase + Olaparib and Cyst(e)inase + Auranofin. The data points above the line indicates Bliss index value from 22Rv1 xenograft tumor from (A) and (B), showing synergistic effects